O'Kelly Brendan, Cronin Colm, Connellan David, Griffin Sean, Connolly Stephen Peter, McGrath Jonathan, Cotter Aoife G, McGinty Tara, Muldoon Eavan G, Sheehan Gerard, Cullen Walter, Doran Peter, McHugh Tina, Vidal Louise, Avramovic Gordana, Lambert John S
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland.
Centre for Experimental Pathogen Host Research, University College Dublin, Dublin 4, Ireland.
JAC Antimicrob Resist. 2021 Jun 30;3(2):dlab085. doi: 10.1093/jacamr/dlab085. eCollection 2021 Jun.
A high proportion of hospitalized patients with COVID-19 receive antibiotics despite evidence to show low levels of true bacterial coinfection.
A retrospective cohort study examining antibiotic prescribing patterns of 300 patients sequentially diagnosed with COVID-19. Patients were grouped into 3 sub-cohorts: Group 1 received no antibiotics, Group 2 received antibiotics for microbiologically confirmed infections and Group 3 was empirically treated with antibiotics for pneumonia. The primary aim was to identify factors that influenced prescription and continuation of antibiotics in Group 3. Secondary aims were to examine differences in outcomes between groups.
In total, 292 patients were included (63 Group 1, 35 Group 2, 194 Group 3), median age was 60 years (IQR 44-76) and the majority were ethnically Irish (62%). The median duration of antibiotics was 7 days (IQR 5-10). In Group 3, factors associated with prescription IV antibiotics on admission were raised C-reactive protein (CRP) (=0.024), increased age (=0.023), higher quick SOFA (=0.016) score and fever >37.5 °C (=0.011). Factors associated with duration of antibiotic course were duration of hypoxia (<0.001) and maximum respiratory support requirement (=0.013). Twenty-one patients in Group 3 had one or more antibiotic escalation events, most (=139) had no escalation or de-escalation of therapy.
Duration of hypoxia and need for respiratory support may have acted as surrogate measures of improvement where usual response measures (CRP, neutrophilia, culture clearance) were absent. Continuous review of antibiotic prescriptions should be at the forefront of clinical management of hospitalized patients with COVID-19.
尽管有证据表明新冠病毒感染患者真正合并细菌感染的比例较低,但仍有很大一部分住院患者接受了抗生素治疗。
一项回顾性队列研究,调查了300例先后确诊为新冠病毒感染患者的抗生素处方模式。患者被分为3个亚组:第1组未接受抗生素治疗,第2组因微生物学确诊感染接受抗生素治疗,第3组因肺炎接受经验性抗生素治疗。主要目的是确定影响第3组抗生素处方和持续使用的因素。次要目的是检查各组之间结局的差异。
总共纳入了292例患者(第1组63例,第2组35例,第3组194例),中位年龄为60岁(四分位间距44 - 76岁),大多数为爱尔兰族裔(62%)。抗生素使用的中位时长为7天(四分位间距5 - 10天)。在第3组中,入院时与静脉注射抗生素处方相关的因素有C反应蛋白升高(CRP)(=0.024)、年龄增加(=0.023)、快速序贯器官衰竭评估(quick SOFA)评分较高(=0.016)以及发热>37.5°C(=0.011)。与抗生素疗程时长相关的因素有缺氧时长(<0.001)和最大呼吸支持需求(=0.013)。第3组中有21例患者发生了一次或多次抗生素升级事件,大多数患者(=139例)没有治疗升级或降级。
在缺乏常规反应指标(CRP、中性粒细胞增多、培养物清除)的情况下,缺氧时长和呼吸支持需求可能起到了病情改善替代指标的作用。对抗生素处方进行持续评估应成为新冠病毒感染住院患者临床管理的首要任务。